Washington University School of Medicine in St. Louis | Strategic Alliance Partners

February 05, 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

September 07, 2012

Siteman patients have access to more than 250 therapeutic clinical trials, and Siteman-affiliated scientists and physicians hold more than $165 million in annual cancer research and related training grants.

August 20, 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

March 27, 2012

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

September 26, 2011

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

September 14, 2011

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

September 12, 2011

Dr. Jeffrey Bradley from Washington University School of Medicine Discusses Key Lung Cancer Topics